Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 22;9(1):69.
doi: 10.1186/s13048-016-0275-2.

p14 expression differences in ovarian benign, borderline and malignant epithelial tumors

Vinicius Duarte Cabral  1 , Marcelle Reesink Cerski  2 , Ivana Trindade Sa Brito  2 , Lucia Maria Kliemann  2
Affiliations

p14 expression differences in ovarian benign, borderline and malignant epithelial tumors

Vinicius Duarte Cabral et al. J Ovarian Res. .

Abstract

Background: Abnormalities in tumor suppressors p14, p16 and p53 are reported in several human cancers. In ovarian epithelial carcinogenesis, p16 and p53 show higher immunohistochemical staining frequencies in malignant tumors and are associated with poor prognoses. p14 was only analyzed in carcinomas, with conflicting results. There are no reports on its expression in benign and borderline tumors. This study aims to determine p14, p16 and p53 expression frequencies in ovarian benign, borderline and malignant tumors and their associations with clinical parameters.

Methods: A cross-sectional study utilizing immunohistochemistry was performed on paraffin-embedded ovarian epithelial tumor samples. Clinical data were collected from medical records. Fisher's exact test and the Bonferroni correction were performed for frequency associations. Survival comparisons utilized Kaplan-Meier and log rank testing. Associations were considered significant when p < 0.05.

Results: p14 absent expression was associated with malignant tumors (60 % positive) (p = 0.000), while 93 % and 94 % of benign and borderline tumors, respectively, were positive. p16 was positive in 94.6 % of carcinomas, 75 % of borderline and 45.7 % of benign tumors (p = 0.000). p53 negative staining was associated with benign tumors (2.9 % positive) (p = 0.016) but no difference was observed between borderline (16.7 %) and malignant tumors (29.7 %) (p = 0.560). No associations were found between expression rates, disease-free survival times or clinical variables. Carcinoma subtypes showed no difference in expression.

Conclusions: This is the first description of p14 expression in benign and borderline tumors. It remains stable in benign and borderline tumors, while carcinomas show a significant absence of staining. This may indicate that p14 abnormalities occur later in carcinogenesis. p16 and p53 frequencies increase from benign to borderline and malignant tumors, similarly to previous reports, possibly reflecting the accumulation of inactive mutant protein. The small sample size may have prevented statistically significant survival analyses and clinical correlations. Future studies should investigate genetic abnormalities in p14 coding sequences and include all types of ovarian epithelial tumors. Bigger sample sizes may be needed for significant associations.

Keywords: ARF; Cancer; Immunohistochemistry; Ovarian epithelial tumor; Ovary; p14; p16; p53.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Percentage of p14, p16 and p53 positive tumors in benign, borderline and malignant tumors
Fig. 2
Fig. 2
Expression scores. Immunohistochemical scores: 0 (0 % positive nuclei), 1 (1–10 % positive nuclei), 2 (11–50 %) positive nuclei, 3 (51–100 % positive nuclei). Arrows indicate positive nuclei
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, Fr. Int Agency Res Cancer. 2014. [cited 2016 Feb 13]. Available from: http://globocan.iarc.fr. Accessed 13 Feb 2016.
    1. Trétarre B, Molinie F, Woronoff A-S, Bossard N, Bessaoud F, Marrer E, et al. Ovarian cancer in France: Trends in incidence, mortality and survival, 1980–2012. Gynecol Oncol. 2015;139:324–9. Elsevier Inc; Available from: http://www.sciencedirect.com/science/article/pii/S009082581530130X. - PubMed
    1. Lowe K, Chia VM, Taylor A, O’Malley C, Kelsh M, Mohamed M, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 2013;130:107–14. doi: 10.1016/j.ygyno.2013.03.026. - DOI - PubMed
    1. Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2012;226:352–64. doi: 10.1002/path.3022. - DOI - PubMed
    1. Wang H, Zhang X, Teng L, Legerski RJ. DNA damage checkpoint recovery and cancer development. Exp Cell Res. 2015;334:350–8. doi: 10.1016/j.yexcr.2015.03.011. - DOI - PubMed

MeSH terms